Status: Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Esophageal Cancer
Participants needed: 148
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Updated: Jan 3, 2025Locations: 1
Eligibility criteria
Have the ability to give informed consent, have signed informed and able to comp... [+8]
Inadequately treated central nervous system metastases or the presence of uncont... [+23]